Biotechnology AssetsXMAD:BST -4.24%19 PB Ratio is 2.35 as of Jun. 27, 2026, which is 26% below its 10-year median of 3.16. GuruFocus rates XMAD:BST with a GF Score™ of 19/100 and a GF Value™ of €0.30 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Biotechnology Assets ranks better than 54.63% on this metric.
The historical rank and industry rank for Biotechnology Assets's PB Ratio or its related term are showing as below:
XMAD:BST'
s PB Ratio Range Over the Past 10 Years
Min: 0.58 Med: 3.16 Max: 11.07
Current: 2.35
During the past 13 years, Biotechnology Assets's highest PB Ratio was 11.07. The lowest was 0.58. And the median was 3.16.
XMAD:BST's PB Ratio is ranked better than 54.63% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs XMAD:BST: 2.35
During the past 12 months, Biotechnology Assets's average Book Value Per Share Growth Rate was -4.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 0.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -30.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Biotechnology Assets was 40.60% per year. The lowest was -67.10% per year. And the median was 4.40% per year.
Back to Basics: PB Ratio
Biotechnology Assets (XMAD:BST) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Biotechnology Assets PB Ratio Related Terms
Biotechnology Assets PB Ratio Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Biotechnology Assets's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's PB Ratio distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Biotechnology Assets (XMAD:BST) has a PB Ratio of 2.35 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biotechnology Assets and its competitors. This is 26% below median its historical median of 3.16. Over the past decade, Biotechnology Assets' PB Ratio has ranged from 0.58 to 11.07. According to the industry distribution chart, Biotechnology Assets ranks #559 out of 1232 companies in the Biotechnology industry, placing it in the top 45.4%.
Is Biotechnology Assets' PB Ratio too high?
Biotechnology Assets' current PB Ratio of 2.35 is 26% below median its 10-year median of 3.16. Over the past 10 years, this metric has ranged from a low of 0.58 to a high of 11.07. The Biotechnology industry median PB Ratio is 2.80. Biotechnology Assets' value of 2.35 is 16.1% below this industry median. Based on the distribution chart, Biotechnology Assets ranks #559 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #559 out of 1232 companies for PB Ratio. This puts Biotechnology Assets in the upper half of its industry. The industry median PB Ratio is 2.80. Biotechnology Assets' value of 2.35 is 16.1% below this benchmark. Historically, Biotechnology Assets' own PB Ratio has ranged from 0.58 to 11.07 over the past decade. While the company's 10-year median is 3.16 vs. the industry median of 2.80, Biotechnology Assets has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotechnology Assets's current PB Ratio of 2.35 is 16.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Biotechnology Assets and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotechnology Assets's current PB Ratio is 2.35, which is 26% below median its own 10-year median of 3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.23 — trading 24.7% below its estimated fair value. The current PB Ratio is 2.35, which is 26% below median its 10-year median of 3.16 and 16.1% below the Biotechnology industry median of 2.80. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current PB Ratio is 2.35 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.23 is trading 24.7% below its estimated GF Value™ of €0.30.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
PB Ratio: 2.35 (26% below median its 10-year median of 3.16)
GF Value™: €0.30 vs. price of €0.23 (24.7% below fair value)
Industry Position: 16.1% below the Biotechnology median (#559 of 1232)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score
Get the complete analysis for XMAD:BST
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
